FindTrial
Sign In

Safety and Efficacy of Vedolizumab in Patients with Severe Ulcerative Colitis in Northern China

Safety and Efficacy of Vedolizumab in Patients with Severe Ulcerative Colitis in Northern China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109833
Enrollment
Unknown
Registered
2025-09-25
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Observation group:None

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: atients with severe ulcerative colitis (total Mayo score > 10) confirmed by clinical, endoscopic, and histologic criteria; Age >= 18 years; Received at least 3 doses of vedolizumab (VDZ).

Exclusion criteria

Exclusion criteria: Age < 18 years; Pregnant or lactating women; Inflammatory bowel disease unclassified (IBD-U); Crohn’s disease, intestinal tuberculosis, intestinal Behçet’s disease, etc.

Design outcomes

Primary

MeasureTime frame
The clinical response rate of VDZ treatment in UC patients for 14 weeks.;—

Secondary

MeasureTime frame
The clinical remission rate of 14-week VDZ treatment in UC patients.;—

Countries

China

Contacts

Public ContactQubo

The Second Affiliated Hospital of Harbin Medical University

qubo_1970@hotmail.com+86 130 3003 9874

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026